Navigating evolving regulatory CMC guidance in the AAV gene therapy field

Cell & Gene Therapy Insights 2023; 9(4), 417–432

DOI: 10.18609/cgti.2023.062

Published: 15 May 2023
Expert Roundtable
M Brewer, A Cockroft, C Fuentes et al.

Elisa Manzotti, CEO of BioInsights, speaks to (pictured left to right) Michael Brewer, Director, Global Principal Consultant, Regulatory, Bioproduction Group, Thermo Fisher Scientific, Alexis Cockroft, Director & Regulatory Consultant, Lex Regulatory Ltd, Christina Fuentes, Senior Consultant, Dark Horse Consulting Group, Christine Le Bec, Head of CMC Gene Therapy, Sensorion Pharma & Yan Zhi, Director and Cell and Gene Therapy Product Owner, Process Engineering, CSL Behring